Skip to content
Calculator
Guide

BPC-157 and cancer: what the angiogenesis argument gets right and wrong

Last updated: November 4, 2026 · 6 min read · By the Grey Peptides Editorial Board

A scientist in a lab coat using a microscope for research in a laboratory setting
Photo by Artem Podrez on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • The worry has a real basis: in lab and rat studies, BPC-157 helps grow new blood vessels through the VEGFR2 receptor, and new blood vessels are part of how tumours grow, a link even the peptide's developers discuss.
  • The step from there to "BPC-157 causes cancer" is untested. Searches of PubMed found no study that tested whether it makes tumours grow, and the developer group argues it controls blood-vessel growth rather than simply driving it.
  • What decides the question is missing: only a handful of small human studies exist (three in a 2026 systematic review, five in FDA's May 2026 briefing), none followed people for cancer, and FDA reviewers found the substance poorly characterised. Anyone with a cancer history should treat it as an unknown.

The argument in one paragraph

BPC-157 Low is a 15-amino-acid peptide offered for sale on many websites 1, and its proposed healing effects include promoting new blood-vessel growth through VEGFR2 and nitric-oxide signalling 2. New blood-vessel growth is also part of how tumours grow, a link the peptide's developers themselves discuss when they contrast healing angiogenesis with tumorigenesis 3. So, the argument runs, a peptide that turns that signalling up could help a hidden tumour along. In a published comment, the peptide's developers say a 2025 literature and patent review by Józwiak and colleagues speculated exactly that, from angiogenesis toward tumour formation 3 1.

What the argument gets right

The mechanism is real, at least in the laboratory. In a 2017 study, BPC-157 increased blood-vessel density in the chick embryo membrane assay and in human endothelial-cell cultures, sped the return of blood flow to the ischaemic hind limbs of rats, and raised the expression of VEGFR2, but not of VEGF-A itself. It also caused VEGFR2 to be taken into the cell and switched on the VEGFR2-Akt-eNOS signalling pathway; blocking that uptake blocked the effect 4. A 2025 review of BPC-157 for muscle and tendon healing describes the same picture: the peptide activates VEGFR2 and nitric-oxide synthesis through the Akt-eNOS axis, promoting blood-vessel growth, particularly in poorly supplied tissues such as tendons 2.

So the concern is not invented. A substance that strengthens the main pro-angiogenic receptor in endothelial cells is, in principle, the kind of substance an oncologist would want to know about.

What the argument cannot show

Plausibility is not evidence of harm. PubMed searches for BPC-157 with "tumor" and with "cancer", run on October 2, 2026, returned 13 and 7 records, and the same counts when re-run on October 27; none tested whether BPC-157 starts or accelerates tumours, and most were written by or with the Zagreb group that developed it 5. The cancer concern is an inference from mechanism, not a finding.

The developer group disputes the inference directly. In a published comment on the Józwiak review, Sikiric and colleagues argue that BPC-157 controls angiogenesis rather than simply promoting it: in their cornea models it does not cause new vessels to grow into the cornea and instead opposes it, and they report anti-tumour effects in their own animal and cell studies 3. An earlier review co-written with the same group even proposed BPC-157 as a possible treatment for cancer cachexia, the muscle wasting of advanced cancer, on the strength of preclinical work 6. These are the claims of the peptide's developers in their own models, not independent confirmation; the Józwiak authors published a reply to the comment 7.

The literature also has quality problems of its own. The Józwiak review states that BPC-157 is not currently on WADA's banned list 1; the 2026 Prohibited List names it in section S0 8. A review that misstates a checkable fact is a reason to read its speculative claims carefully too.

What FDA reviewers found

When the FDA's compounding committee considered BPC-157 in July 2026, agency staff proposed not adding it to the list of substances pharmacies may compound. Their briefing document found it not well characterised, and found a lack of information on safety and immunogenicity 9. The committee voted 8 to 6, with one abstention, to recommend it anyway, according to published reports of the meeting; FDA has posted no tallies 10 11. As of October 27, 2026, FDA's 503A category list, last updated May 14, 2026, did not place BPC-157 in Category 1, and it is not on the 503A bulks list 12. None of this is a cancer finding in either direction; it is a statement that the basic safety information is missing.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 under the forms, routes and conditions in its Appendix B 13. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

What nobody knows

Human data are minimal. The 2025 musculoskeletal review counted three small pilot studies in people, for knee pain, interstitial cystitis and intravenous safety and pharmacokinetics; no adverse effects were reported, and none of the three was a cancer study 2. A 2026 systematic review that searched to June 1, 2026 found the same three, 30 people in all 14; FDA's May 2026 briefing counts five clinical studies, about 108 people, adding two enema studies, in healthy volunteers and in ulcerative colitis 9; and a September 2026 report described three dental patients given it with TB-500 and other drugs 15. None of them was a cancer study. The searches above found no study that has followed people who use BPC-157 for tumour outcomes, or given it to people with cancer 5.

For someone with active cancer, a cancer history or a high inherited risk, the honest position is that BPC-157's effect on tumours is unknown, and that its known mechanism points in the direction that would matter if the effect turned out to be real. That is a conversation to have with an oncologist before, not after. Our wider guide to peptides and cancer covers the other peptides people ask about.

Frequently asked questions

Does BPC-157 cause cancer?

No study has shown that it does, and our PubMed searches found none that has tested it. The concern comes from its mechanism: in lab and rat studies it promotes blood-vessel growth through VEGFR2, the pathway tumours use. Only a handful of small human studies exist (three in a 2026 systematic review, five in FDA's May 2026 briefing), none designed to detect cancer.

Is BPC-157 safe for someone with a history of cancer?

Its effect on tumours is unknown. Because it promotes blood-vessel growth in laboratory models, people with active cancer or a cancer history should discuss it with their oncologist; there is no human evidence either way.

Does BPC-157 have anti-cancer effects?

Its developers report anti-tumour effects in their own animal and cell models and have proposed it for cancer cachexia, but these findings have not been independently confirmed or tested in people.

What did the FDA say about BPC-157's safety?

FDA staff found, in a briefing dated May 11, 2026, that BPC-157 is not well characterised and that information on its safety and immunogenicity is lacking. The compounding committee recommended it 8 to 6 in July, as reported by law firms (FDA posts no tallies); as of October 27, 2026, FDA had not put it in Category 1 or on the 503A list.

Sources

  1. Józwiak, M., et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel), 18(2). PMID: 40005999 · doi:10.3390/ph18020185
  2. McGuire, F. P., et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 18(12), 611-619. PMID: 40789979 · doi:10.1007/s12178-025-09990-7
  3. Sikiric, P., et al. (2025). BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel), 18(10). PMID: 41155565 · doi:10.3390/ph18101450
  4. Hsieh, M. J., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl), 95(3), 323-333. PMID: 27847966 · doi:10.1007/s00109-016-1488-y
  5. Grey Peptides searches of PubMed, 'BPC 157 tumor' (13 records) and 'BPC 157 cancer' (7 records), run October 2 and re-run October 27, 2026, with the same counts; author affiliations read on the records.
  6. Kang, E. A., et al. (2018). BPC157 as Potential Agent Rescuing from Cancer Cachexia. Curr Pharm Des, 24(18), 1947-1956. PMID: 29898649 · doi:10.2174/1381612824666180614082950
  7. Józwiak, M., et al. (2025). Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185". Pharmaceuticals (Basel), 18(10). PMID: 41155566 · doi:10.3390/ph18101451
  8. World Anti-Doping Agency. Prohibited List 2026, section S0 (names BPC-157); read October 2, 2026. WADA
  9. US FDA. Briefing document: evaluation of BPC-157 (free base) and BPC-157 acetate for inclusion on the 503A bulk drug substances list, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026, memo dated May 11, 2026; read October 2, 2026, date re-read October 28, 2026; summary points re-checked against our PCAC record October 27, 2026. FDA
  10. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): BPC-157 recommended 8 yes, 6 no, 1 abstain. Read October 27, 2026. FDA has posted no minutes or tallies. Cited without a link.
  11. US FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting page: briefing documents, questions, agenda and roster; no minutes or vote tallies posted (content current as of August 6, 2026). Read October 27, 2026. FDA
  12. US FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026): BPC-157 in no category. Read October 27, 2026. FDA
  13. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
  14. Poolton, J. T., et al. (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 92(3). PMID: 42885452 · doi:10.52628/92.3.15837
  15. Froum, S., et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7, 1907109. PMID: 42876687 · doi:10.3389/froh.2026.1907109

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead